Almirall and Absci partner to develop AI-designed therapeutics for dermatological diseases

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

source https://www.news-medical.net/news/20231120/Almirall-and-Absci-partner-to-develop-AI-designed-therapeutics-for-dermatological-diseases.aspx

Comments

Post a Comment

Popular posts from this blog

New and surprising evidence that ChatGPT can perform several intricate tasks relevant to handling complex medical and clinical information

Researchers evaluated the performance of an AI model named ChatGPT to perform clinical reasoning on the United States Medical Licensing Exam (USMLE). source https://www.news-medical.net/news/20230213/New-and-surprising-evidence-that-ChatGPT-can-perform-several-intricate-tasks-relevant-to-handling-complex-medical-and-clinical-information.aspx
Read more

"Deep sequencing" of the genome informs diagnoses and treatment of vascular anomalies

Researchers from Children's Hospital of Philadelphia (CHOP) recently discovered that extremely thorough "deep sequencing" of the genome in tissue samples and cell-free DNA of patients with potentially life-threatening vascular anomalies captured several genetic variants related to disease that were not captured with conventional genetic sequencing methods. source https://www.news-medical.net/news/20230601/Deep-sequencing-of-the-genome-informs-diagnoses-and-treatment-of-vascular-anomalies.aspx
Read more